ORPHA:3310
Tetrasomy 9p syndrome
Also known as: Isochromosome 9p
Query health: suspect — Only one of 2 strategies returned hits (phrase).
Publications
50
36.4th percentile
Trials
0
Interventional, condition-specific
Researchers
451
Distinct authors in sample
Gene link
—
Readiness
1/6
Stages with a signal
Clinical definition (Orphanet)
Tetrasomy 9p is a rare anomaly characterized by pre- and postnatal growth retardation, psychomotor delay, mild to moderate , , microcephaly, features (ocular hypertelorism, low-set, malformed ears, bulbous/beaked nose, microretrognathia, enophthalmos/micropthalmia, epicanthus, strabismus), cleft lip/palate, skeletal abnormalities (hypoplastic nails/distal phalanges, short stature, short neck, contractures), heart defects, renal and urogenital malformations (renal hypoplasia, genital hypoplasia, cryptorchidism).
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0018030
- MeSH:C538027
- UMLS:C0795832
Additional Mondo synonyms (2)
Chromosome 9, Tetrasomy 9p · tetrasomy type 9p
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
1/6 stages with a signal
Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
50 matched papers (19 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
50
50 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
50 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
19 in the last 10 years · high confidence · 36.4th percentile (publications denominator)
Phrase hits: 50 · MeSH hits: 0
Who's working on it?
451
Distinct author names in 50 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Liehr T4 papers · 2023
Institute of Human Genetics and Anthropology, Jena University Hospital, Jena, Thuringia, Germany.
Papers in Europe PMC - 02Gajjar A2 papers · 2025
Department of Oncology, Division of Neuro-Oncology, St Jude Children's Research Hospital, Memphis, TN, USA.
Papers in Europe PMC - 03Garcia-Lopez J2 papers · 2025
Department of Developmental Neurobiology, St Jude Children's Research Hospital, Memphis, TN, USA.
Papers in Europe PMC - 04Gudenas BL2 papers · 2025
Department of Developmental Neurobiology, St Jude Children's Research Hospital, Memphis, TN, USA.
Papers in Europe PMC - 05Hadley J2 papers · 2025
Department of Developmental Neurobiology, St Jude Children's Research Hospital, Memphis, TN, USA.
Papers in Europe PMC - 06Jiang Y2 papers · 2025
Genetic and Metabolic Central Laboratory, Birth Defect Prevention Research Institute, Maternal and Child Health Hospital, Children's Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530002, China.
Papers in Europe PMC - 07Kojic M2 papers · 2025
Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland, Australia.
Papers in Europe PMC - 08Li Y2 papers · 2025
Fujian Key Laboratory for Prenatal Diagnosis and Birth Defect, Fujian Provincial Maternity and Children's Hospital, Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Papers in Europe PMC - 09Lu M2 papers · 2025
Tisch Cancer Institute, Division of Hematology/Oncology, and.
Papers in Europe PMC - 10Luo J2 papers · 2025
Genetic and Metabolic Central Laboratory, Birth Defect Prevention Research Institute, Maternal and Child Health Hospital, Children's Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530002, China. luojingsi0815@126.com.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Tetrasomy 9p syndrome" OR "Isochromosome 9p" OR "Chromosome 9, Tetrasomy 9p" OR "tetrasomy type 9p"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Tetrasomy 9p syndrome" OR "Isochromosome 9p" OR "Chromosome 9, Tetrasomy 9p" OR "tetrasomy type 9p" OR "partial trisomy/tetrasomy of chromosome 9"
Recall-expansion terms: partial trisomy/tetrasomy of chromosome 9
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T22:49:29.982Z